Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities

Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities

High-dose methotrexate is a cornerstone agent in the chemotherapeutic treatment of patients with osteosarcoma. However, patients often develop methotrexate-induced toxicities. We aim to identify determinants of methotrexate-induced toxicities in osteosarcoma patients by investigating the relation be...

Full description

Bibliographic Details
Main Authors: Evelien G. E. Hurkmans, Marije J. Klumpers, Sita H. Vermeulen, Melanie M. Hagleitner, Uta Flucke, H. W. Bart Schreuder, Hans Gelderblom, Johannes Bras, Henk-Jan Guchelaar, Marieke J. H. Coenen, D. Maroeska W. M. te Loo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
methotrexate
osteosarcoma
pharmacogenetics
absorption, distribution, metabolism, and excretion (ADME)
plasma levels
toxicity
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01241/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01241/full

Similar Items